Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 10 of about 44 citing Korytkowski: Glimepiride improves both first and second phases of insulin secretion in type.... (0.09 sec) 

The role of sulphonylureas in the management of type 2 diabetes mellitus

- adisonline.com [PDF] 
M Rendell - Drugs, 2004 - ingentaconnect.com
The sulphonylureas act by triggering insulin release from the pancreatic β cell. Abstract A specific
site on the adenosine triphosphate (ATP)-sensitive potassium channels is occupied by sulphonylureas
leading to closure of the potassium channels and subsequent opening of calcium ...
Cited by 87 - Related articles - BL Direct - All 7 versions

Clinical significance of targeting postprandial and fasting hyperglycemia in …


V Fonseca - Current Medical Research and Opinion®, 2003 - informahealthcare.com
Measurement of glycosylated hemoglobin (HbA1C) remains the gold standard for the assessment
of glycemic control in patients with type 2 diabetes. Recent investigations have studied the correlations
between HbA1C levels and other aspects of glucose metabolism, specifically, ...
Cited by 31 - Related articles - BL Direct - All 8 versions

Triple therapy with glimepiride in patients with type 2diabetes mellitus inadequately …


VL Roberts, J Stewart, M Issa, B Lake, R Melis - Clinical therapeutics, 2005 - Elsevier
This was a multicenter, randomized, double-blind,1026 placebo-controlled, parallel-group,
2-arm study consisting of a 4-week stabilization and eligibility period and a 26-week treatment
period. Patients with a diagnosis of type 2 diabetes for a minimum of 1 year received ...
Cited by 30 - Related articles - All 3 versions

Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in …


M Tan, D Johns, G González Gálvez, O Antúnez, G … - Clinical therapeutics, 2004 - Elsevier
Methods: This was a multicenter, 52-week, double-blind, parallel-group trial. Patients were randomized
to receive monotherapy with either glimepiride (2 mg QD initially) or pioglitazone (15 mg QD
initially). Doses were titrated (maximal doses: pioglitazone 45 mg, glimepiride 8 mg) to ...
Cited by 28 - Related articles - All 3 versions

Glimepiride versus pioglitazone combination therapy in subjects with type 2 …


G Umpierrez, M Issa, A Vlajnic - Current Medical Research and …, 2006 - informahealthcare.com
Guillermo umpierreza, Maher issab and Aleksandra Vlajnicc ... Address for
correspondence: Guillermo Umpierrez, MD, Associate Professor of Medicine, Emory University
School of Medicine, 49 Jesse Hill Jr. Drive, Atlanta, GA 30303, USA. Tel.: +1 404 778 ...
Cited by 24 - Related articles - BL Direct - All 5 versions

Sulfonylurea treatment of type 2 diabetes mellitus: focus on glimepiride


MT Korytkowski - Pharmacotherapy, 2004 - PPI
Sulfonylureas, which have evolved through two generations since their introduction nearly 50
years ago, remain the most frequently prescribed oral agents for treatment of patients with type
2 diabetes mellitus. Glyburide, glipizide, and glimepiride, the newest sulfonylureas, are as ...
Cited by 20 - Related articles - BL Direct - All 4 versions

Change in patients' body weight after 12 months of treatment with glimepiride or …


S Martin, H Kolb, J Beuth, R Leendert, B Schneider, WA … - Diabetologia, 2003 - Springer
Aims/hypothesis. Our study compared the effects of glimepiride or glibenclamide treatment on
body weight over 12 months of treatment in patients with Type 2 diabetes in routine outpatient
practice. Methods. This new retrospective study design used data from physicians in a ...
Cited by 16 - Related articles - BL Direct - All 3 versions

[PDF] Use of glimepiride and insulin sensitizers in the treatment of type 2 diabetes—a …


A Ramachandran, C Snehalatha, J Salini, V Vijay - JAPI, 2004 - japi.org
Aim : Short-term efficacy of glimepiride, metformin and pioglitazone in newly diagnosed type
2 diabetes was compared with a group treated with diet and exercise. Effects on insulin secretion
and sensitivity were also assessed. Methods : New type 2 diabetic subjects, aged 30-60 ...
Cited by 15 - Related articles - View as HTML - All 4 versions

Repaglinide has more beneficial effect on cardiovascular risk factors than …


MR Rizzo, M Barbieri, R Grella, N Passariello, G … - Diabetes and Metabolism, 2005 - Elsevier
Aim our study is to compare the effects of repaglinide vs glimepiride administration on cardiovascular
risk factors after meal test. Thus, after 2 weeks washout period, a 3-month randomised,
cross-over parallel group trial of repaglinide (1 mg × 2/day) vs glimepiride (2 mg/day) in ...
Cited by 15 - Related articles - All 3 versions

Repaglinide is more efficient than glimepiride on insulin secretion and post- …


MR Rizzo, M Barbieri, R Grella, N Passariello, M … - Diabetes and Metabolism, 2004 - Elsevier
Both R and G significantly but similarly lowered fasting glucose levels and improved fasting plasma
insulin levels vs baseline. Hyperglycemic clamp showed that both 1 st (129.15 ± 23.6 vs 106.90
± 18.6 pmol/L; p = 0.01) and 2 nd phase (189.42 ± 34.4 vs 144.21 ± 37.3 pmol/L; p = ...
Cited by 13 - Related articles - BL Direct - All 3 versions


Result Page: 

1

2

3

4

5

Next


 


Go to Google Home - About Google - About Google Scholar

©2009 Google